Cytokine receptor zcytor17
First Claim
1. An isolated polynucleotide, wherein the polypeptide comprises a sequence of amino acid residues that is selected from the group consisting of:
- (a) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 227 (Pro);
(b) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 519 (Glu);
(c) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 543 (Leu);
(d) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 544 (Lys) to amino acid number 732 (Val);
(e) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 544 (Lys) to amino acid number 649 (Ile);
(f) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 732 (Val);
(g) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 20 (Ala) to amino acid number 649 (Ile);
(h) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 1 (Met) to amino acid number 732 (Val); and
(i) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 1 (Met) to amino acid number 649 (Ile).
1 Assignment
0 Petitions
Accused Products
Abstract
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
-
Citations
32 Claims
-
1. An isolated polynucleotide, wherein the polypeptide comprises a sequence of amino acid residues that is selected from the group consisting of:
-
(a) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 227 (Pro);
(b) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 519 (Glu);
(c) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 543 (Leu);
(d) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 544 (Lys) to amino acid number 732 (Val);
(e) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 544 (Lys) to amino acid number 649 (Ile);
(f) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 732 (Val);
(g) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 20 (Ala) to amino acid number 649 (Ile);
(h) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 1 (Met) to amino acid number 732 (Val); and
(i) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 1 (Met) to amino acid number 649 (Ile). - View Dependent Claims (3, 4, 5)
-
-
2. An isolated polynucleotide comprising a sequence selected from the group consisting of:
-
(a) a polynucleotide as shown in SEQ ID NO;
1 from nucleotide number 228 to amino acid number 851;
(b) a polynucleotide as shown in SEQ ID NO;
1 from nucleotide number 228 to amino acid number 1727;
(c) a polynucleotide as shown in SEQ ID NO;
1 from nucleotide number 228 to amino acid number 1799;
(d) a polynucleotide as shown in SEQ ID NO;
1 from nucleotide number 1800 to amino acid number 2366;
(e) a polynucleotide as shown in SEQ ID NO;
45 from nucleotide number 1791 to amino acid number 2108;
(f) a polynucleotide as shown in SEQ ID NO;
1 from nucleotide number 228 to amino acid number 2366;
(g) a polynucleotide as shown in SEQ ID NO;
45 from nucleotide number 219 to amino acid number 2108;
(h) a polynucleotide as shown in SEQ ID NO;
1 from nucleotide number 171 to amino acid number 2366;
(i) a polynucleotide as shown in SEQ ID NO;
45 from nucleotide number 162 to amino acid number 2108; and
(j) a polynucleotide sequence complementary to (a) through (i).
-
-
6. An expression vector comprising the following operably linked elements:
-
a transcription promoter;
a DNA segment encoding a polypeptide comprising an amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to 732 (Val) or an amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 20 (Ala) to 649 (Ile); and
a transcription terminator, wherein the promoter is operably linked to the DNA segment, and the DNA segment is operably linked to the transcription terminator. - View Dependent Claims (7, 8, 9, 10, 11, 12, 13, 22, 24, 29)
-
-
14. A DNA construct encoding a fusion protein, the DNA construct comprising:
a first DNA segment encoding a polypeptide comprising a sequence of amino acid residues selected from the group consisting of;
(a) the amino acid sequence of SEQ ID NO;
2 from amino acid number 1 (Met), to amino acid number 19 (Ala);
(b) the amino acid sequence of SEQ ID NO;
54 from amino acid number 1 (Met), to amino acid number 32 (Ala);
(c) the amino acid sequence of SEQ ID NO;
2 from amino acid number 20 (Ala), to amino acid number 227 (Pro);
(d) the amino acid sequence of SEQ ID NO;
2 from amino acid number 20 (Ala), to amino acid number 519 (Glu);
(e) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 543 (Leu);
(f) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 520 (Ile) to amino acid number 543 (Leu);
(g) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 544 (Lys) to amino acid number 732 (Val);
(h) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 544 (Lys) to amino acid number 649 (Ile);
(i) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 732 (Val); and
(j) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 20 (Ala) to amino acid number 649 (Ile); and
at least one other DNA segment encoding an additional polypeptide, wherein the first and other DNA segments are connected in-frame; and
wherein the first and other DNA segments encode the fusion protein. - View Dependent Claims (15, 16, 17)
-
18. An isolated polypeptide comprising a sequence of amino acid residues selected from the group consisting of:
-
(a) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 227 (Pro);
(b) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 519 (Glu);
(c) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 543 (Leu);
(d) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 544 (Lys) to amino acid number 732 (Val);
(e) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 544 (Lys) to amino acid number 649 (Ile);
(f) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 732 (Val);
(g) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 20 (Ala) to amino acid number 649 (Ile);
(h) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 1 (Met) to amino acid number 732 (Val); and
(i) the amino acid sequence as shown in SEQ ID NO;
46 from amino acid number 1 (Met) to amino acid number 649 (Ile). - View Dependent Claims (19, 20, 21, 28)
-
-
23. An isolated polypeptide comprising an amino acid segment selected from the group consisting of:
-
(a) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 227 (Pro);
(b) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 519 (Glu);
(c) the amino acid sequence as shown in SEQ ID NO;
18; and
(d) the amino acid sequence as shown in SEQ ID NO;
22,wherein the polypeptide is substantially free of transmembrane and intracellular domains ordinarily associated with hematopoietic receptors.
-
-
25. A method of producing an antibody to a polypeptide comprising:
inoculating an animal with a polypeptide selected from the group consisting of;
(a) a polypeptide consisting of 9 to 713 amino acids, wherein the polypeptide comprises a contiguous sequence of amino acids in SEQ ID NO;
2 from amino acid number 20 (Ala), to amino acid number 732 (Val);
(b) a polypeptide consisting of 9 to 630 amino acids, wherein the polypeptide comprises a contiguous sequence of amino acids in SEQ ID NO;
46 from amino acid number 20 (Ala), to amino acid number 649 (Ile);
(c) a polypeptide comprising amino acid number 20 (Ala) to 227 (Pro) of SEQ ID NO;
2;
(d) a polypeptide comprising amino acid number 20 (Ala) to 519 (Glu) of SEQ ID NO;
2;
(e) a polypeptide comprising amino acid number 20 (Ala) to 543 (Leu) of SEQ ID NO;
2;
(f) a polypeptide comprising amino acid number 544 (Lys) to 732 (Val) of SEQ ID NO;
2;
(g) a polypeptide comprising amino acid number 544 (Lys) to 649 (Ile) of SEQ ID NO;
46;
(h) a polypeptide comprising amino acid number 20 (Ala) to 732 (Val) of SEQ ID NO;
2;
(i) a polypeptide comprising amino acid number 20 (Ala) to 649 (Ile) of SEQ ID NO;
46;
(j) a polypeptide comprising amino acid number 1 (Met) to 732 (Val) of SEQ ID NO;
2;
(k) a polypeptide comprising amino acid number 1 (Met) to 649 (Ile) of SEQ ID NO;
46,(l) a polypeptide comprising amino acid residues 43 through 48 of SEQ ID NO;
2;
(m) a polypeptide comprising amino acid residues 157 through 162 of SEQ ID NO;
2;
(n) a polypeptide comprising amino acid residues 158 through 163 of SEQ ID NO;
2;
(o) a polypeptide comprising amino acid residues 221 through 226 of SEQ ID NO;
2; and
(p) a polypeptide comprising amino acid residues 426 through 431 of SEQ ID NO;
2; and
wherein the polypeptide elicits an immune response in the animal to produce the antibody; and
isolating the antibody from the animal. - View Dependent Claims (26, 27)
-
30. A method for detecting a cytokine receptor ligand within a test sample, comprising:
contacting a test sample with a polypeptide comprising an amino acid sequence from the group consisting of;
(a) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 227 (Pro);
(b) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 20 (Ala) to amino acid number 519 (Glu);
(e) the amino acid sequence as shown in SEQ ID NO;
18;
the amino acid sequence as shown in SEQ ID NO;
22; and
detecting the binding of the polypeptide to a ligand in the sample. - View Dependent Claims (31, 32)
Specification